Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses IGMS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IGMS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Fred Schwarzer | $646,797 | $0 | $868,050 | $1,336,743 | $355,738 | $0 | $0 | $3,207,328 |
| Chief Executive Officer, President and Director | ||||||||
| Bruce Keyt | 492,326 | 0 | 337,575 | 519,845 | 221,458 | 0 | 0 | 1,571,204 |
| Chief Scientific Officer | ||||||||
| Chris Takimoto | 486,492 | 0 | 337,575 | 519,845 | 218,900 | 0 | 0 | 1,562,812 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Fred Schwarzer | $3,207,328 | — | — | — |
| Bruce Keyt | 1,571,204 | — | — | — |
| Chris Takimoto | 1,562,812 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chris Takimoto | OPTION | — | — | — | — | — | $519,845 |
| Chris Takimoto | RSU | — | — | — | — | — | 337,575 |
| Fred Schwarzer | RSU | — | — | — | — | — | 868,050 |
| Bruce Keyt | OPTION | — | — | — | — | — | 519,845 |
| Fred Schwarzer | OPTION | — | — | — | — | — | 1,336,743 |
| Bruce Keyt | RSU | — | — | — | — | — | 337,575 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chris Takimoto | $337,575 | $0 | $519,845 | 0.0% |
| Fred Schwarzer | 868,050 | 0 | 1,336,743 | 0.0% |
| Bruce Keyt | 337,575 | 0 | 519,845 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chris Takimoto | RSU | 9,375 | — | $77,906 |
| Chris Takimoto | Option | 42,188 | 17.11 | — |
| Fred Schwarzer | Option | 6,250 | 40.27 | — |
| Fred Schwarzer | Option | 36,459 | 91.5 | — |
| Fred Schwarzer | Option | 109,688 | 12.86 | — |
| Bruce Keyt | Option | 14,584 | 91.5 | — |
| Bruce Keyt | RSU | 9,375 | — | 77,906 |
| Bruce Keyt | Option | 42,188 | 17.11 | — |
| Bruce Keyt | Option | 42,657 | 12.86 | — |
| Chris Takimoto | Option | 42,657 | 12.86 | — |
| Bruce Keyt | RSU | 26,250 | — | 218,138 |
| Fred Schwarzer | Option | 196,875 | 17.11 | — |
| Chris Takimoto | Option | 59,375 | 68.01 | — |
| Chris Takimoto | RSU | 26,250 | — | 218,138 |
| Bruce Keyt | Option | 3,125 | 40.27 | — |
| Fred Schwarzer | RSU | 67,500 | — | 560,925 |
with a goal of ensuring that the compensation we offer to our executive officers is competitive and fair
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William StrohlIndependent · Research and Clinical Development (Chair) | $90,000 | — | $146,594 | $0 | $0 | $236,594 |
| Julie HambletonIndependent · Audit · Research and Clinical Development (Chair) | 57,500 | — | 146,594 | 0 | 0 | 204,094 |
| Michael LobergIndependent · Compensation · Departed during FY | — | 35,950 | 146,594 | 0 | 0 | 182,544 |
| M. Kathleen BehrensIndependent · Audit (Chair) · Compensation · Nominating/Governance | — | 31,704 | 146,594 | 0 | 0 | 178,298 |
| Christina Teng TopsoeIndependent · Compensation (Chair) · Nominating/Governance (Chair) | 0 | 29,247 | 146,594 | 0 | 0 | 175,841 |
| Felix J. BakerIndependent · Research and Clinical Development | — | 21,955 | 146,594 | 0 | 0 | 168,549 |
| Elizabeth H.Z. ThompsonIndependent · Audit · Compensation · Nominating/Governance · Research and Clinical Development · Newly elected | 15,285 | — | 152,250 | 0 | 0 | 167,535 |
| Jakob Haldor TopsoeIndependent | 0 | 19,498 | 146,594 | 0 | 0 | 166,092 |
| Michael LeeIndependent | — | 19,498 | 146,594 | 0 | 0 | 166,092 |
| Fred SchwarzerEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $162,785 |
| Equity awards (grant-date value) | $157,852 |
| All other compensation | $0 |
| Total cost of the board | $320,637 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | IGM Biosciences | 2023 | Fred Schwarzer | $646,797 | $868,050 | $1,336,743 | $355,738 | $3,207,328 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Fred Schwarzer | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Summary Compensation Table” · page 34. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |
| 2 | Section 01, Bruce Keyt | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Summary Compensation Table” · page 34. As printed: 1,571,204. Filing ↗machine: r4 · c21 · span 837011–837020 |
| 3 | Section 01, Chris Takimoto | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Summary Compensation Table” · page 34. As printed: 1,562,812. Filing ↗machine: t15 · r6 · c21 · span 849179–849188 |
| 4 | Section 03, Chris Takimoto OPTION | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c13 · span 847131–847138 |
| 5 | Section 03, Chris Takimoto RSU | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c9 · span 846107–846114 |
| 6 | Section 03, Fred Schwarzer RSU | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r2 · c9 · span 821748–821755 |
| 7 | Section 03, Bruce Keyt OPTION | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c13 · span 834963–834970 |
| 8 | Section 03, Fred Schwarzer OPTION | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r2 · c13 · span 822772–822781 |
| 9 | Section 03, Bruce Keyt RSU | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c9 · span 833939–833946 |
| 10 | Section 08, William Strohl | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 236,594. Filing ↗machine: t10 · r7 · c15 · span 396788–396795 |
| 11 | Section 08, Julie Hambleton | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 204,094. Filing ↗machine: t10 · r4 · c15 · span 383240–383247 |
| 12 | Section 08, Michael Loberg | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 182,544. Filing ↗machine: t10 · r6 · c15 · span 392322–392329 |
| 13 | Section 08, M. Kathleen Behrens | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 178,298. Filing ↗machine: t10 · r3 · c15 · span 378774–378781 |
| 14 | Section 08, Christina Teng Topsoe | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 175,841. Filing ↗machine: t10 · r9 · c15 · span 405896–405903 |
| 15 | Section 08, Felix J. Baker | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 168,549. Filing ↗machine: t10 · r2 · c15 · span 374303–374310 |
| 16 | Section 08, Elizabeth H.Z. Thompson | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 167,535. Filing ↗machine: t10 · r8 · c15 · span 401423–401430 |
| 17 | Section 08, Jakob Haldor Topsoe | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 166,092. Filing ↗ |
| 18 | Section 08, Michael Lee | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 166,092. Filing ↗machine: t10 · r5 · c15 · span 387696–387703 |
| 19 | Section 08, Fred Schwarzer | DEF 14A | 2024-04-26 | 0000950170-24-049091 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 21 | Section 09b board cost (computed) | Computed | — | computed | Cash 162,785 + equity 157,852 + all other 0 = 320,637, summed across the director compensation table rows.machine: formula: Σ = 320,637 |
| 22 | IGM Biosciences (subject), Section 10b CEO total | DEF 14A | 2024-04-26 | 0000950170-24-049091 | CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |